The anti-inflammatory therapeutics market would grow at a CAGR of 4.5% over the predicted time frame. The market is expected to increase in value from US$ 102.37 Bn in 2022 to US$ 127.5 Bn in 2030.
The on anti-inflammatory therapeutics Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.
Download Free Sample@ https://www.precedenceresearch.com/sample/2229
Report Scope of the Anti-Inflammatory Therapeutics Market
| Report Coverage | Details |
| Market Size in 2022 |
USD 102.37 Billion |
| Market Size by 2030 |
USD 127.5 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 4.5% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Drug Class, Indication, Application, Distribution Channel, and Geography |
| Companies Mentioned | Eli Lily and Company, AstraZeneca PLC, Amgen Inc., F. Hoffman, Abbvie, Inc., Johnson & Johnson, GlaxoSmithKline, Merck & CO., Inc., Novartis, Pfizer, Inc., La Roche AG, Ferring Pharmaceuticals, Bioventus, Zimmer Biomet Holdings, Inc., Flexion Therapeutics, Inc |
A recent report provides crucial insights along with application based and forecast information in the Global Anti-inflammatory therapeutics Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Anti-inflammatory therapeutics market.
A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.
Companies and Manufacturers Covered
The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Anti-inflammatory therapeutics market are included as given below:
Market Segments
By Drug Class
- Anti-inflammatory Biologics
- Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- Corticosteroids
By Indication
- Arthritis
- Rheumatoid Arthritis
- Osteoarthritis
- Ankylosing Spondylitis
- Psoriatic Arthritis
- Gout
- Respiratory diseases
- Asthma
- Chronic obstructive pulmonary disease (COPD)
- Multiple sclerosis
- Psoriasis
- Inflammatory bowel disease
- Crohn's Disease
- Ulcerative Colitis
- Other inflammatory diseases
By Application
- Autoimmune
- Inflammatory Diseases (Rheumatoid Arthritis Psoriasis)
- Respiratory Diseases
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa (MEA)
Report Objectives
- To define, describe, and forecast the global anti-inflammatory therapeutics market based on product, and region
- To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
- To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
- To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the anti-inflammatory therapeutics market
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Anti-Inflammatory Therapeutics Market
5.1. COVID-19 Landscape: Anti-Inflammatory Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Anti-Inflammatory Therapeutics Market, By Drug Class
8.1. Anti-Inflammatory Therapeutics Market, by Drug Class, 2022-2030
8.1.1. Anti-inflammatory Biologics
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Corticosteroids
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Anti-Inflammatory Therapeutics Market, By Indication
9.1. Anti-Inflammatory Therapeutics Market, by Indication, 2022-2030
9.1.1. Arthritis
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Respiratory diseases
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Multiple sclerosis
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Psoriasis
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Inflammatory bowel disease
9.1.5.1. Market Revenue and Forecast (2017-2030)
9.1.6. Other inflammatory diseases
9.1.6.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Anti-Inflammatory Therapeutics Market, By Application
10.1. Anti-Inflammatory Therapeutics Market, by Application, 2022-2030
10.1.1. Autoimmune
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Inflammatory Diseases (Rheumatoid Arthritis Psoriasis)
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Respiratory Diseases
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Anti-Inflammatory Therapeutics Market, By Distribution Channel
11.1. Anti-Inflammatory Therapeutics Market, by Distribution Channel, 2022-2030
11.1.1. Hospital Pharmacy
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Retail Pharmacy
11.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Anti-Inflammatory Therapeutics Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.1.2. Market Revenue and Forecast, by Indication (2017-2030)
12.1.3. Market Revenue and Forecast, by Application (2017-2030)
12.1.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.1.5.2. Market Revenue and Forecast, by Indication (2017-2030)
12.1.5.3. Market Revenue and Forecast, by Application (2017-2030)
12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Indication (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Application (2017-2030)
12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.2. Market Revenue and Forecast, by Indication (2017-2030)
12.2.3. Market Revenue and Forecast, by Application (2017-2030)
12.2.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.5.2. Market Revenue and Forecast, by Indication (2017-2030)
12.2.5.3. Market Revenue and Forecast, by Application (2017-2030)
12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Indication (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Application (2017-2030)
12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.7.2. Market Revenue and Forecast, by Indication (2017-2030)
12.2.7.3. Market Revenue and Forecast, by Application (2017-2030)
12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.8.2. Market Revenue and Forecast, by Indication (2017-2030)
12.2.8.3. Market Revenue and Forecast, by Application (2017-2030)
12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.2. Market Revenue and Forecast, by Indication (2017-2030)
12.3.3. Market Revenue and Forecast, by Application (2017-2030)
12.3.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.5.2. Market Revenue and Forecast, by Indication (2017-2030)
12.3.5.3. Market Revenue and Forecast, by Application (2017-2030)
12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Indication (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Application (2017-2030)
12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.7.2. Market Revenue and Forecast, by Indication (2017-2030)
12.3.7.3. Market Revenue and Forecast, by Application (2017-2030)
12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Indication (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Application (2017-2030)
12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.2. Market Revenue and Forecast, by Indication (2017-2030)
12.4.3. Market Revenue and Forecast, by Application (2017-2030)
12.4.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.5.2. Market Revenue and Forecast, by Indication (2017-2030)
12.4.5.3. Market Revenue and Forecast, by Application (2017-2030)
12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Indication (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Application (2017-2030)
12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.7.2. Market Revenue and Forecast, by Indication (2017-2030)
12.4.7.3. Market Revenue and Forecast, by Application (2017-2030)
12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Indication (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Application (2017-2030)
12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.5.2. Market Revenue and Forecast, by Indication (2017-2030)
12.5.3. Market Revenue and Forecast, by Application (2017-2030)
12.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.5.5.2. Market Revenue and Forecast, by Indication (2017-2030)
12.5.5.3. Market Revenue and Forecast, by Application (2017-2030)
12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Indication (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Application (2017-2030)
12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 13. Company Profiles
13.1. Eli Lily and Company
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. AstraZeneca PLC
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Amgen Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. F. Hoffman
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Abbvie, Inc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Johnson & Johnson
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. GlaxoSmithKline
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Merck & CO., Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Novartis
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Pfizer, Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
0 Comments